As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: July 25, 2013
by Kate Kelland for The Globe And Mail:
Health systems could be “overwhelmed” by the costs of coping with mental illnesses such as dementia, depression and addiction if nothing is done now to boost investment in research, leading neuroscientists said on Thursday.
Publishing a study that put the estimated costs of brain disorders in Britain alone at more than £112-billion ($176-billion) a year, they said mental illness research needed to attract the same funding levels as illnesses such as cancer and heart diseases to be able to reduce the burden.
“No group of chronic diseases costs the world more than brain disorders,” said Barbara Sahakian, a professor at Cambridge University and president of the British Association of Psychopharmacology.
She said that with a third of the adult population suffering from a mental disorder every year and aging populations increasing that proportion, “if we don’t do something soon … we will be overwhelmed by brain disorders.”
The study, published in the Journal of Psychopharmacology, found that in 2010, there were around 45 million diagnoses of brain disorders in Britain.
The diagnosed illnesses included more than eight million cases of anxiety disorder and nearly four million cases of mood disorders, such as depression and bipolar disorder.
Annually, the five most costly disorders in terms of medicines, health care and indirect costs, such as time off work and loss of productivity, were dementia, psychotic disorders, mood disorders, addiction and anxiety disorders.
A Europe-wide study published in 2011 put the total cost of brain disorders at almost €800-billion ($1-trillion) and said the region was facing a political, social and financial “ticking bomb” as more people fall prey to mental illnesses.
Some big pharmaceutical companies, in Europe particularly GlaxoSmithKline and AstraZeneca, have been backing away from investment into research on how the brain works and affects behaviour because they say it is not profitable enough. That puts the onus on governments and health charities to find stump up funding for neuroscience.
David Nutt, a professor of neuropsychopharmacology at Imperial College London, said the situation required a co-ordinated effort at European and national levels to change policy maker and public attitudes to funding mental-health research.
“Diseases need to be ranked according to their economic burden,” he said, noting that funding for dementia research in Britain is around £50-million ($77-million) a year, less than a 10th of the annual funding given to cancer research, which gets around £590-million.
“We have an enormous disparity between research investment and the scale of the disorders.,” he said.
Thirty-six million people worldwide suffer from Alzheimer’s disease and dementia. In Canada, 25,000 new cases are diagnosed each year. Those sobering numbers have researchers around the globe racing to come up with new ways to...
he Food and Drug Administration issued new guides on drug development for neurological disorders. This sets the stage for possible treatments for Alzheimer’s. The disease-oriented development guide documents will provide details on how researchers...
For young adults with autosomal dominant Alzheimer’s disease (AD), molecular markers can identify changes associated with the disease before clinical onset, according to a study published online Feb. 12 in JAMA Neurology. Yakeel T. Quiroz, Ph.D., from Massachusetts...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.